Please login to the form below

Not currently logged in
Email:
Password:

Gilead makes senior changes

Expanded roles for Andrew Cheng and Taiyin Yang

Gilead Sciences has responded to its growing pharma business in infectious diseases with two senior appointments.

Dr Andrew Cheng has been promoted from his current role as senior VP, HIV therapeutics and development operations to an executive VP position.

Similarly Dr Taiyin Yang is promoted from senior VP to executive VP with responsibility for pharmaceutical development and manufacturing.

Norbert Bischofberger, the company's chief scientific officer, said: “Andrew and Taiyin have both demonstrated leadership in bringing groups together to help expedite the development and manufacturing of products – ultimately allowing the company to reach patients in need more quickly.

“These promotions recognise their achievements and dedication to bringing innovative new therapies to patients around the world.”

Dr Cheng has been with Gilead since 1999 and was appointed to his senior VP role in 2009.

Dr Yang is also a veteran of the company having joined in 1993. She was appointed senior VP in 2005.

4th February 2015

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....
Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
Some of the most popular and innovative ways of using our cutting-edge asynchronous and synchronous virtual tools for Medical Affairs teams....